Silihan lan utang jangka dawa perusahaan Neurotrope (SNPX)
The Synaptogenix, Inc. (SNPX) price chart on the GURU.Markets platform demonstrates long-term debt amounting to 0.00. This biotech startup is researching methods to combat Alzheimer's, planning to generate future profits through licensing royalties to partners. Currently, the micro-cap is fighting for survival and patent extensions, lacking market weight against industry behemoths. The business currently relies on grants while developing drugs for the regeneration of neural connections.
SNPX (Neurotrope): rincian analitis lan laporan miturut indikator
When constructing a long-term portfolio, it is critical to assess the stability of the issuer's capital structure. This indicator aggregates all credit obligations with maturities exceeding one year, measuring the level of debt load on the business. For Synaptogenix, Inc. (SNPX), this determines the financial resources available for the development of a unique Alzheimer's disease therapy. A potential monopoly in the treatment of cognitive impairment must justify the borrowings. Evaluate the change in the issuer's long-term liabilities to analyze the company's solvency.